Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Pancreatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Ovarian Neoplasms 1Non Hematologic Cancers 1Neoplasms 1Lung Neoplasms 1

Interventions

Carboplatin 341Paclitaxel 262Cisplatin 233Pemetrexed 226Docetaxel 206Erlotinib Hydrochloride 193Gemcitabine 178pembrolizumab 137Bevacizumab 121Radiotherapy 118Nivolumab 84Gefitinib 73Vinorelbine 64Cetuximab 58atezolizumab 47Afatinib 46durvalumab 44osimertinib 41Radiosurgery 35Ipilimumab 34Drug Therapy 32Taxes 30Albumin-Bound Paclitaxel 29130-nm albumin-bound paclitaxel 29Surgical Procedures, Operative 28Etoposide 25Irinotecan 24Sorafenib 21Cyclophosphamide 20Radiation 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Carcinoma, Non-Small-Cell Lung × defactinib × Clear all
NCT04620330 2024-01-12

RAMP202

Verastem, Inc.

Phase 2 Completed
90 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01951690 2017-04-13

Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

Verastem, Inc.

Phase 2 Completed
55 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡